ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 8276.9 | 7474.7 | 6268.3 |
| Other income | 130.3 | 140.7 | 79.0 |
| Total income | 8407.2 | 7615.4 | 6347.3 |
| Profit before exceptional items & tax | 2017.4 | 2059.3 | 1415.5 |
| Exceptional items | 0.0 | 131.3 | 0.0 |
| Profit before tax | 2017.4 | 1928.0 | 1415.5 |
| Net profit | 1415.0 | 1460.4 | 1219.1 |
| Operating margin | 24.0% | 25.3% | 22.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +16.10% |
|---|---|
| Net profit, quarter on quarter | -3.10% |
| Revenue, year on year | +32.00% |
| Operating profit, year on year | +41.20% |
| Operating profit, quarter on quarter | -1.60% |
NSE results filing, NSE: LUPIN. Figures extracted from the filing.
Lupin Ltd: key numbers
- Share price
- ₹2,023.40
- Market cap
- ₹92,529 Cr
- Revenue (annual)
- ₹27,958 Cr
- Net profit (annual)
- ₹5,333 Cr
- P/E (TTM)
- 17.8×Sector 43.8×
- Promoter holding
- 46.84%-0.01% QoQ
- FII holding
- 23.28%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Lupin Ltd
All →Lupin Earnings Call Transcript: Key Takeaways
Revenue up 11% to ₹7,827 Cr, but EBITA margin fell to 25.1% from 31.3%; US down 13.4% QoQ on Tolvaptan erosion; management hedged FY28 outlook.
Lupin Investor Presentation: Key Takeaways
Q2 FY27 net sales ₹77,855mn (+14% YoY); EBITDA ₹19,574mn, margin 25.1% (vs 31.3%); net income ₹11,553mn (-21.8% YoY). US pressured by competition/LOE.
Lupin Management Change
Lupin appointed Akhil Gupta as an Additional and Independent Director effective 3 November 2026, for five years to 2031. The appointment is subject to shareholder approval.
Lupin Q2 FY27 Results: Net Profit ₹1,155 Cr, Down 22.2% YoY
Lupin Ltd reported revenue from operations of ₹7,827 Cr (+11.1% YoY) and net profit of ₹1,155 Cr (-22.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1,155 Cr · -22.2% YoY
Lupin Product Launch
Lupin launched generic Raltegravir Tablets 600 mg in the United States. It is first-to-file, with 180-day exclusivity.
Lupin Regulatory Approval
Lupin received US FDA approval for its generic Amifampridine Tablets 10 mg ANDA. As a first-to-file applicant, it is eligible for 180-day shared generic exclusivity.